These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 17917977)

  • 1. Amyloid-associated amyloidosis in a HCV carrier with non-Hodgkin's lymphoma who had been treated with autologous stem cell transplantation and rituximab.
    Kubo Y; Tasaka T; Sano F; Matsuhashi Y; Nishimura H; Sadahira Y; Wada H; Sugihara T
    Leuk Lymphoma; 2007 Oct; 48(10):2075-8. PubMed ID: 17917977
    [No Abstract]   [Full Text] [Related]  

  • 2. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning autologous transplant.
    Kuan JW; Law CS; Wong XQ; Ko CT; Awang ZH; Chew LP; Chang KM
    Appl Radiat Isot; 2016 Oct; 116():13-21. PubMed ID: 27472826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin's lymphoma patients receiving autologous hematopoietic stem cell transplantation.
    Lee MY; Chiou TJ; Hsiao LT; Yang MH; Lin PC; Poh SB; Yen CC; Liu JH; Teng HW; Chao TC; Wang WS; Chen PM
    Ann Hematol; 2008 Apr; 87(4):285-9. PubMed ID: 17943285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation.
    Tsai D; Moore H; Hardy C; Porter D; Loh E; Vaughn D; Luger S; Schuster S; Stadtmauer E
    Bone Marrow Transplant; 1999 Sep; 24(5):521-6. PubMed ID: 10482937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
    Hosing C; Saliba RM; Körbling M; Acholonu S; McMannis J; Anderlini P; Giralt S; De Lima M; Okoroji GJ; Couriel DR; Champlin R; Khouri IF; Donato ML
    Leuk Lymphoma; 2006 Jul; 47(7):1290-4. PubMed ID: 16923559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma.
    Bhatt VR; Vose JM
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1073-95. PubMed ID: 25459180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy.
    Tsutsumi Y; Ichiki K; Shiratori S; Kawamura T; Tanaka J; Asaka M; Imamura M; Masauzi N
    Int J Lab Hematol; 2009 Aug; 31(4):468-70. PubMed ID: 18294236
    [No Abstract]   [Full Text] [Related]  

  • 9. Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab.
    Hirayama Y; Kohda K; Konuma Y; Hirata Y; Kuroda H; Fujimi Y; Shirao S; Kobune M; Takimoto R; Matsunaga T; Kato J
    Intern Med; 2009; 48(1):57-60. PubMed ID: 19122357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period.
    Lim SH; Esler WV; Zhang Y; Zhang J; Periman PO; Burris C; Townsend M
    Leuk Lymphoma; 2008 Jan; 49(1):152-3. PubMed ID: 18203024
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma.
    Akhtar S; Maghfoor I
    J Clin Oncol; 2005 Sep; 23(25):6261; author reply 6262. PubMed ID: 16135496
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma.
    Lemieux B; Tartas S; Traulle C; Espinouse D; Thieblemont C; Bouafia F; Alhusein Q; Antal D; Salles G; Coiffier B
    Bone Marrow Transplant; 2004 May; 33(9):921-3. PubMed ID: 15034544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
    Nishio M; Endo T; Fujimoto K; Yamamoto S; Obara M; Yamaguchi K; Takeda Y; Goto H; Kasahara I; Sato N; Koike T
    Eur J Haematol; 2009 Feb; 82(2):143-7. PubMed ID: 19018870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of AIDS-associated, primary CNS lymphoma with rituximab- and methotrexate-based chemotherapy and autologous stem cell transplantation.
    Wolf T; Kiderlen T; Atta J; Stephan C; Kann G; Brodt HR; Brandts C
    Infection; 2014 Apr; 42(2):445-7. PubMed ID: 24442720
    [No Abstract]   [Full Text] [Related]  

  • 15. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
    Paul F; Rossi JF; Cartron G
    Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should rituximab be used prior to autologous stem-cell transplantation for non-Hodgkin's lymphoma?
    Rodriguez J
    Nat Clin Pract Oncol; 2005 Feb; 2(2):74-5. PubMed ID: 16264876
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Aksentijevich I; Flinn IW
    Cancer Control; 2002; 9(2):99-105. PubMed ID: 12008655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma.
    Holmberg LA; Maloney D; Bensinger W
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):135-9. PubMed ID: 17026825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is autologous stem cell transplantation for transformed follicular lymphoma still justifiable?
    Dickinson M
    Leuk Lymphoma; 2012 May; 53(5):754-5. PubMed ID: 22239667
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association.
    Cohen AD; Zhou P; Xiao Q; Fleisher M; Kalakonda N; Akhurst T; Chitale DA; Moscowitz C; Dhodapkar MV; Teruya-Feldstein J; Filippa D; Comenzo RL
    Br J Haematol; 2004 Feb; 124(3):309-14. PubMed ID: 14717777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.